Navigation Links
Alseres Pharmaceuticals, Inc. to Present at The Neurotech Industry Investing & Partnering Conference
Date:5/5/2008

HOPKINTON, Mass., May 5 /PRNewswire-FirstCall/ -- Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE) today announced that the Company will participate in a panel entitled "Traumatic Brain and Spinal Cord Injury" at the Neurotech Industry Investing & Partnering Conference in Boston, MA, Thursday, May 8, 2008. The session will focus on emerging treatments of major traumatic injuries to the Central Nervous System (CNS). The event is the premier partnering and investing conference for the segment of the healthcare sector focused on neurological technologies.

(Logo: http://www.newscom.com/cgi-bin/prnh/20070608/NEF043LOGO )

About Alseres

Alseres Pharmaceuticals, Inc. (ALSE) is engaged in the development of therapeutic and diagnostic products primarily for disorders in the central nervous system (CNS). The Company maintains a world-class intellectual property position in the field of regenerative therapeutics. The Company's focus is reflected in several important initiatives. CETHRIN, a recombinant- protein-based drug designed to promote nerve repair after acute spinal cord injury, demonstrated positive interim results in a Phase I/IIa clinical trial. The Company's research and pre-clinical programs include, Inosine for the treatment of spinal cord injury and stroke, Oncomodulin for the treatment of ocular injury and disease and research programs directed at a number of regenerative therapies including bone repair. The Company has a robust molecular imaging development program targeting diagnosis of Parkinson's disease and potentially dementia and ADHD. The Company's lead molecular imaging product candidate is ALTROPANE which is in Phase III clinical trials for the diagnosis of Parkinsonian Syndromes including Parkinson's Disease. The Company has research collaborations with Harvard Medical School and Children's Hospital Boston.

Alseres is a trademark and CETHRIN and ALTROPANE are registered trademarks of Alseres Pharmaceuticals, Inc.

Contact: Sharon Correia -- 508-497-2360 ext 224 scorreia@alseres.com or

Adam Friedman -- 212-981-2529 ext 18 adam@adam-friedman.com

http://www.alseres.com


'/>"/>
SOURCE Alseres Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Alseres Pharmaceuticals, Inc. Complies With NASDAQ Rule Regarding Recently Filed 10-K
2. Alseres Pharmaceuticals, Inc. Raises $5 Million
3. Alseres Pharmaceuticals, Inc. to Present at New York Society of Security Analysts Conference
4. Lotus Pharmaceuticals, Inc. Announces Resignation of Director Mel Rothberg
5. Aida Pharmaceuticals, Inc. Announces Availability of Downloadable Corporate Synopsis on its Website
6. Lotus Pharmaceuticals, Inc. Announces Fourth Quarter and Fiscal Year 2007 Results
7. Lotus Pharmaceuticals, Inc. Announces Conference Call to Discuss Fourth Quarter and Fiscal Year 2007 Results
8. Aida Pharmaceuticals, Inc. Announces New Antibiotic Drug Under Development
9. Bayer HealthCare Pharmaceuticals, Amerinet Extend Contrast Media Agreement
10. Barr Pharmaceuticals, Inc. Executive Bios
11. Jazz Pharmaceuticals, Inc. Announces LUVOX CR Launch Plans and Reports Development Pipeline Progress at Investor Day Presentation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... 2017 , ... “A Prophets Bones”: a thrilling adventure that reveals the mystery of Kevin’s purpose. ... that his parents and teachers had asked of him that he had neglected to do, ... defy the Almighty Creator. There were some who would have felt themselves to be special ...
(Date:3/27/2017)... ... March 27, 2017 , ... New patients who have sleep apnea ... with or without a referral. Sleep apnea is often left untreated because patients are ... headaches and chronic snoring. , Dr. Braasch seeks to raise awareness of sleep ...
(Date:3/27/2017)... ... March 27, 2017 , ... ... custom smile makeovers without requiring a referral. Trimble Dental offers a ... treatment, cosmetic dentistry and dental implants. Whether patients have discolored, crooked or missing ...
(Date:3/27/2017)... ... 27, 2017 , ... Drs. Justin Kolnick, Kara Diamond, Randall Barton, Keith Hope ... the key role this treatment plays in protecting oral health, along with the benefits ... those who need a root canal in White Plains, NY or their second location ...
(Date:3/27/2017)... ... 2017 , ... This is the second major release since ... 2014. It is the culmination of collaborative efforts by members of the OSEHRA ... Member Zato Health co-funded the ONC certification and provided key technical support throughout ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... 27, 2017 Medtec Europe ... more than 600 exhibitors from 70 countries the ... solutions that will advance the medical technology industry. ... the Messe Stuttgart, Stuttgart, Germany ... platform showcasing the key trends and insights across ...
(Date:3/27/2017)... March 27, 2017  Sophiris Bio Inc. (NASDAQ: ... a clinical late-stage biopharmaceutical company developing topsalysin (PRX302) ... today reported fourth quarter and full year 2016 ... Key Corporate Highlights: Advanced ... Cancer. During 2016, the Company reported successful results ...
(Date:3/27/2017)... VANCOUVER , March 27, 2017 /PRNewswire/ - INVICTUS ... OTC: IVITF; FRA: 8IS) Invictus MD is pleased to ... common shares for trading on the TSX Venture Exchange.  ... the TSXV follows a year of significant achievements for ... The successful test crops at AB Laboratories Inc. ("AB ...
Breaking Medicine Technology: